CMO consolidation strategy has shifted from building scale and adding geographies towards niche technologies and biologics, according to the founder of trade association PBOA.
While pharma is increasing use of automation and data integration tools in process development and manufacturing, it lags behind in electronic documentation of quality control, according to Lonza Biologics QC director Jessica Jean.
Alexion says it is looking to bring more manufacturing capabilities in-house, despite its CMO partner Lonza recently setting up a dedicated suite at a site in New Hampshire.
Pfizer and GlaxoSmithKline have agreed to work together on the development of a new version of the former's continuous processing technology for oral solid dosage (OSD) drugs.
Pollution caused by pharmaceuticals in wastewater is a major challenge facing the industry, but researchers in Greece may have come up with a solution.
A GlaxoSmithKline plant in China that was hit by an explosion in the summer has had its Good Manufacturing Practice (GMP) certificate revoked by the UK medicines regulator.
Pfizer has announced an extra 90 production jobs at Dublin’s Grange Castle biomanufacturing site, adding to the 40 hires it plans for its API facilities in Cork, Ireland.
As pharma sells off manufacturing capacity and outsources to large and specialist CMOs, smart contract houses will have an opportunity to grab market share in a currently fragmented sector, say experts.
Pharma is looking to condense the number of contract manufacturers it works with, says Aesica which has launched a service to help manage its customers’ supply chain.
CDMO Ajinomoto Althea is opening a new facility to offer outsourced ADC (antibody drug conjugate) and HPAPI (highly potent active pharmaceutical ingredient) manufacturing, the Californian company has announced.
Big Pharma has returned to Europe for its API sourcing due to reasons of quality and reliability, according to the European Fine Chemicals Group (EFCG).
API suppliers should be allowed to make process improvements without having to seek re-approval says consultant Girish Malhotra, who argues that the current rules create inefficiency and waste.
Rival injectable drug contractors were felled by a stricter MHRA take on rules says Symbiosis' CEO who is confident his firm's compliance record will help it thrive.
Catalent says it is contemplating expanding its Wisconsin single-use biologics facility as strong demand from SMEs and biotechs has almost filled current capacity.
DSM may have narrowed the focus of its pharmaceutical business in recent years, but the Netherlands-based supplier is still trying to win drug industry customers at a trade show in Spain.
Trilantic Capital Partners Europe has bought a majority stake in Doppel Farmaceutici, citing the growth potential of Europe’s contracting market as the driver.
Contractor Trenzyme GmbH has licensed a CHO cell line-based expression system from Swiss firm Celonic AG in a deal designed to expand its service offering.
MannKind has cut more jobs in efforts to streamline operations, leaving the inhalable insulin manufacturer around a third smaller than this time last year.
The US FDA has issued a product safety alert and recommended a compounding pharmacy cease manufacturing operations after observing unsanitary conditions at a Californian facility.
Drug companies still outsource to make fixed costs variable rather than to try and improve their public profiles through sustainable sourcing according to a Deloitte analyst.
